The cardiometabolic syndrome and calcium channel blocker combination drugs.
On April 18, 2007, a panel was convened to discuss the metabolic syndrome and its relationship to the renin-angiotensin system. James R. Sowers, MD, Professor of Medicine and Physiology and Director of the Diabetes Research Center, University of Missouri-Columbia, Columbia, moderated the panel. George L. Bakris, MD, Professor of Medicine, University of Chicago, Chicago, IL; Henry R. Black, MD, Clinical Professor of Internal Medicine, New York University School of Medicine, New York, NY; and Thomas D. Giles, MD, Professor of Medicine, Tulane University School of Medicine, New Orleans, LA, participated in the discussion. This expert panel discussion was supported by Novartis and each author received an honorarium from Novartis for time and effort spent participating in the discussion and reviewing the transcript for important intellectual content prior to publication. The authors maintained full control of the discussion and the resulting content of this article.
Sowers
James R
JR
Diabetes Research Center, University of Missouri-Columbia, Columbia, MO, USA.
Bakris
George L
GL
Black
Henry R
HR
Giles
Thomas D
TD
D000959:Antihypertensive Agents / Q000008:administration & dosage*; D002121:Calcium Channel Blockers / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D024821:Metabolic Syndrome / Q000188:drug therapy* / Q000503:physiopathology; D012084:Renin-Angiotensin System / Q000502:physiology*